The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Novo Nordisk would not comment on the new pharmacy benefits arrangements. But a spokesperson for Eli Lilly told CNBC, "Lilly will continue to work with those in health care, government and the ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S ...

Reuters reports that online weight loss company Noom will sell low-dose versions of Novo Nordisk's Wegovy. Compounding pharmacies like Noom have struggled to figure out how to sell GLP-1 weight ...

Novo Nordisk Pharma (Thailand) Ltd. is advancing its commitment to sustainable weight management among Thais through the launch of the “From My Weight to My Heart” campaign, aimed at reducing ...

In its first-quarter 2025 investor letter, ClearBridge Large Cap Value Strategy highlighted stocks such as Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages in the research and ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases. The deal could be worth up ...

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker on Friday abruptly announced that longtime CEO Lars Fruergaard ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership and board of directors. Per the press release, Lars Fruergaard ...